Breast cancer: Noninvasive and special situations

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 10, 2010, Pages 1182-1207

  Carlson, Robert W ^a   Allred, D Craig ^b   Anderson, Benjamin O ^c   Burstein, Harold J ^d   Carter, W Bradford ^e   Edge, Stephen B ^f   Erban, John K ^g   Farrar, William B ^h   Forero, Andres ⁱ   Giordano, Sharon Hermes ^j   Goldstein, Lori J ^k   Gradishar, William J ^l   Hayes, Daniel F ^m   Hudis, Clifford A ⁿ   Ljung, Britt Marie ^o   Marcom, P Kelly ^p   Mayer, Ingrid A ^q   McCormick, Beryl ⁿ   Pierce, Lori J ^m   Reed, Elizabeth C ^r   Smith, Mary Lou ^v   Somlo, George ^s   Topham, Neal S ^k   Ward, John H ^t   Winer, Eric P ^d   Wolff, Antonio C ^u   more..

^a STANFORD CANCER INSTITUTE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p DUKE CANCER INSTITUTE   (United States)

^q VANDERBILT INGRAM CANCER CENTER   (United States)

^r NEBRASKA MEDICAL CENTER   (United States)

^s CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^t UNIVERSITY OF UTAH   (United States)

^u JOHNS HOPKINS UNIVERSITY   (United States)

^v NONE

more..

Author keywords

Breast conserving therapy; Ductal carcinoma in situ; Endocrine therapy; Lobular carcinoma in situ; Mastectomy; NCCN clinical practice guidelines; NCCN guidelines; Noninvasive breast cancer; Radiation therapy; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CITALOPRAM; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; LORAZEPAM; ONDANSETRON; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; VENLAFAXINE;

ADJUVANT THERAPY; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST FIBROADENOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSARCOMA PHYLLOIDES; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; FETUS MALFORMATION; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; KIDNEY FAILURE; LOBULAR CARCINOMA IN SITU; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; PAGET NIPPLE DISEASE; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK REDUCTION; TERATOGENICITY;

EID: 78951490233     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0087     Document Type: Review

References (117)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.
4. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
5. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.
6. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
7. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 2003;98:2740-2741.
8. White J, Morrow M, Moughan J, et al. Compliance with breastconservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893-904.
9. Wilkinson NW, Shahryarinejad A, Winston JS, et al. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:38-43.
10. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1999;11:155-168.
11. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130.
12. Rudiger T, Höfler H, Kreipe HH, et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-882.
13. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Cancer Netw 2009;7(Suppl 6):S1-24.
14. Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-381.
15. DAKO HercepTest [package insert]. Carpinteria, CA: DAKO Corp; 2004.
16. Pathway HER2 [package insert]. Tucson, AZ: Ventana Medical Systems, Inc; 2004.
17. INFORM HER2/neu gene detection system [package insert]. Tucson, AZ: Ventana Medical Systems, Inc; 2001.
18. Pathvysion HER2/neu method [package insert]. Downers Grove, IL: Vysis, Inc; 2001.
19. HER2 FISH pharmDx Kit [package insert]. Glostrup, Denmark: Dako Denmark A/S; 2005.
20. SPOT-Light HER2 CISH kit [package insert], Camarillo, CA: Invitrogen Corp; 2008.
21. Anderson S, Gilkerson E, Klein P. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat 2002;76(Suppl 1):S68. Abstract 235.
22. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
23. Paik S, Tan-Chiu E, Bryant J, et al. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin [abstract]. Breast Cancer Res and Treat 2002;76(Suppl 1):S31. Abstract 9.
24. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038.
25. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721.
26. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-6607.
27. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S1-22.
28. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-147.
29. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235-237.
30. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-687.
31. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991;15:209-221.
32. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:1133-1143.
33. Haagensen CD, Bodian C, Haagensen DE Jr. Breast carcinoma. Risk and Detection. Philadelphia, PA: W.B. Saunders; 1981.
34. Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg 1990;56:428-432.
35. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23:5534-5541.
36. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006;4:511-522.
37. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
38. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
39. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
40. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 2005;63:1514-1521.
41. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
42. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-452.
43. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528-533.
44. Emdin SO, Granstrand B, Ringberg A, et al. SweCDIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomized trial in a population offered mammography screening. Acta Oncol 2006;45:536-543.
45. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Austraila, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
46. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008;26:1247-1252.
47. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-2274.
48. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-1461.
49. Di Saverio S, Catena F, Santini D, et al. 259 patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008;109:405-416.
50. Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 2008;6:61.
51. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
52. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
53. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 2005;190:521-525.
54. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009;27:1615-1620.
55. Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol 2007;14:2202-2208.
56. Edge SB, Sheldon DG. Counterpoint: sentinel lymph node biopsy is indicated for ductal carcinoma in situ. J Natl Compr Canc Netw 2003;1:207-212.
57. Cody HS III, Van Zee KJ. Point: sentinel lymph node biopsy is indicated for ductal carcinoma in situ. J Natl Compr Canc Netw 2003;1:199-206.
58. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720.
59. Waddell BE, Stomper PC, DeFazio JL, et al. Postexcision mammography is indicated after resection of ductal carcinoma-insitu of the breast. Ann Surg Oncol 2000;7:665-668.
60. Tan-Chiu E, Wang J, Costantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302-307.
61. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
62. Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24 [abstract]. Breast Cancer Res Treat 2003;76(Suppl 1):Abstract 30.
63. Sakorafas GH, Blanchard K, Sarr MG, Farley DR. Paget's disease of the breast. Cancer Treat Rev 2001;27:9-18.
64. Marcus E. The management of Paget's disease of the breast. Curr Treat Options Oncol 2004;5:153-160.
65. Kollmorgen DR, Varanasi JS, Edge SB, Carson WE III. Paget's disease of the breast: a 33-year experience. J Am Coll Surg 1998;187:171-177.
66. Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget's disease of the nipple. J Am Coll Surg 2008;206:316-321.
67. Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005;40:363-367.
68. Pierce LJ, Haffty BG, Solin LJ, et al. The conservative management of Paget's disease of the breast with radiotherapy. Cancer 1997;80:1065-1072.
69. Singh A, Sutton RJ, Baker CB, Sacks NP. Is mastectomy overtreatment for Paget's disease of the nipple? Breast 1999;8:191-194.
70. Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2001;91:472-477. (Pubitemid 32105691)
71. Kawase K, Dimaio DJ, Tucker SL, et al. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 2005;12:391-397.
72. Marshall JK, Griffith KA, Haffty BG, et al. Conservative management of Paget disease of the breast with radiotherapy: 10-and 15-year results. Cancer 2003;97:2142-2149.
73. Marshall JK, Griffith KA, Haffty BG, et al. Conservative management of Paget disease of the breast with radiotherapy: 10-and 15-year results. Cancer 2003;97:2142-2149.
74. Laronga C, Hasson D, Hoover S, et al. Paget's disease in the era of sentinel lymph node biopsy. Am J Surg 2006;192:481-483. (Pubitemid 44344188)
75. Sukumvanich P, Bentrem DJ, Cody HS III, et al. The role of sentinel lymph node biopsy in Paget's disease of the breast. Ann Surg Oncol 2007;14:1020-1023.
76. Telli ML, Horst KC, Guardino AR, et al. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw 2007;5:324-330.
77. Anderson BO, Lawton TJ, Lehman CD, Moe RE. Phyllodes tumors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:991-206.
78. Salvadori B, Cusumano F, Del Bo R, et al. Surgical treatment of phyllodes tumors of the breast. Cancer 1989;63:2532-2536.
79. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-4628.
80. Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000;89:1502-1511.
81. Mangi AA, Smith BL, Gadd MA, et al. Surgical management of phyllodes tumors. Arch Surg 1999;134:487-492.
82. Pandey M, Mathew A, Kattoor J, et al. Malignant phyllodes tumor. Breast J 2001;7:411-416.
83. Tse GM, Lee CS, Kung FY, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol 2002;118:522-526.
84. Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001;184:1504-1512.
85. Middleton LP, Amin M, Gwyn K, et al. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 2003;98:1055-1060.
86. Gwyn K, Theriault R. Breast cancer during pregnancy. Oncology (Williston Park) 2001;15:39-46.
87. Yang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006;239:52-60.
88. Kuerer HM, Gwyn K, Ames FC, Theriault RL. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 2002;131:108-110.
89. Annane K, Bellocq JP, Brettes JP, Mathelin C. Infiltrative breast cancer during pregnancy and conservative treatment. Fetal Diagn Ther 2005;20:442-444.
90. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J 2008;14:250-254.
91. Mondi MM, Cuenca RE, Ollila DW, et al. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 2007;14:218-221.
92. Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol 2007;29;5:10.
93. Keleher A, Wendt R III, Delpassand E, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J 2004;10:492-495.
94. Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004;15:1348-1351.
95. Pandit-Taskar N, Dauer LT, Montgomery L, et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006;47:1202-1208.
96. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004;15:146-150.
97. Johnson PH, Gwyn K, Gordon N, et al. The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 540.
98. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.
99. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997;74:207-220.
100. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006;107:1219.
101. Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, et al. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 2004;5:317-319.
102. Potluri V, Lewis D, Burton GV. Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature. Clin Breast Cancer 2006;7:167-170.
103. Gainford M, Clemons M. Breast cancer in pregnancy: are taxanes safe? Clin Oncol 2006;18:159.
104. Mir O, Berveiller P, Ropert S, et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 2008;19:607-613.
105. Garcia-Manero M, Royo MP, Espinos J, et al. Pregnancy associated breast cancer. Eur J Surg Oncol 35:215-218.
106. Fanale MA, Uyei AR, Theriault RL, et al. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 2005;6:354-356.
107. Waterson AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 2006;24:321-322.
108. Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005;105:642-643.
109. Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 2007;110:507-510.
110. Bader AA, Schlembach D, Tamussino KF, et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007;8:79-81.
111. Pant S, Landon MB, Blumenfeld M, et al. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 2008;26:1567-1569.
112. Witzel ID, Mueller V, Harps E, et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2007;19:191-195.
113. Shrim A, Garcia-Bournissen F, Maxwell C, et al. Favorable pregnancy outcome following trastuzumab (Herceptin) use during pregnancy - case report and updated literature review. Reprod Toxicol 2007;23:611-613.
114. Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 2006;7:339-341.
115. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008;247:732-738.
116. Varadarajan R, Edge SB, Yu J, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006;71:456-459.
117. Olson JA, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7:411-415.